Recent studies have demonstrated that HDAC inhibitors such as Resminostat have additive or synergistic activities in combination with other novel pharmaceutical agents and conventional chemotherapeutic agents for HCC treatment [15]. Here, HDAC9 is linked to hepatocellular carcinoma.